Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRM-0334 in frontotemporal dementia with granulin mutation
2014-001489-85Phase 2Completed
- Sponsor
- FORUM Pharmaceuticals
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of FRM-0334 in frontotemporal lobar degeneration (FTLD) (3 arms), sponsored by FORUM Pharmaceuticals. Primary endpoint: Mean plasma progranulin concentration increase. Started Aug 2014; status: completed.
02
Drugs
FRM-0334
03
Conditions
frontotemporal lobar degeneration (FTLD)
Beyond the preview
Go deeper on 2014-001489-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001489-85.